Picture of Icon logo

ICLR Icon News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapSuper Stock

Ireland's ICON Q1 results beat estimates on commercial momentum

Ireland's ICON Q1 results beat estimates on commercial momentum


Overview

  • Ireland clinical research firm's Q1 revenue up 0.9% yr/yr, beating analyst expectations

  • Q1 adjusted EPS beat analyst expectations

  • Company reaffirmed 2026 full-year guidance


Outlook

  • ICON reaffirms 2026 revenue guidance of $7.85 bln to $8.15 bln

  • Company maintains 2026 adjusted diluted EPS outlook of $10.00 to $11.00

  • ICON expects incremental progress through 2026, citing strong commercial momentum


Result Drivers

  • COMMERCIAL MOMENTUM - Co said strong net bookings and a book-to-bill ratio of 1.42 were driven by robust gross award activity and low cancellations

  • PARTNERSHIPS - Improved win rates supported by partnerships added in H2 2025 and two new partnerships in the quarter, per CEO Barry Balfe

  • BUSINESS MIX - Co said Q1 financial performance was impacted, as expected, by business mix


Company press release: ID:nBw7BNwsa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Revenue

Beat

$2.03 bln

$1.99 bln (14 Analysts)

Q1 Adjusted EPS

Beat

$2.50

$2.42 (12 Analysts)

Q1 Net Income

$104.75 mln

Q1 Adjusted EBITDA

Beat

$317.73 mln

$314.21 mln (14 Analysts)

Q1 Operating Income

Miss

$173.73 mln

$265.47 mln (11 Analysts)

Q1 Pretax Profit

Miss

$127.56 mln

$224.28 mln (10 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 8 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for ICON PLC is $160.00, about 13.7% above its June 22 closing price of $140.73

  • The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 9 three months ago


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Icon

See all news